Thymosin Alpha-1 (10 mg Vial) Dosage Protocol

Thymosin Alpha-1 (10 mg Vial) Dosage Protocol

Quickstart Highlights

Thymosin Alpha-1 (Tα1) is a 28–amino acid peptide originally isolated from the thymus gland, recognized for its broad immunomodulatory properties[1]. It has been investigated as an immune enhancer in chronic viral infections (hepatitis B/C, HIV/AIDS) and critical illness (sepsis, COVID-19)[2][3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical daily range: 300–500 mcg once daily (gradual titration).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and use within 7 days.
Thymosin Alpha-1 10mg Vial

Dosing & Reconstitution Guide

Subcutaneous, once daily

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Week 1 300 mcg (0.3 mg) 9 units (0.09 mL)
Weeks 2–8 500 mcg (0.5 mg) 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously. This 8‑week protocol begins at 300 mcg to assess tolerance, then increases to a maintenance dose of 500 mcg daily from Week 2 onward. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges[4][5]. Treatment durations of 8–16 weeks are commonly reported in literature.

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (Thymosin Alpha-1, 10 mg each):

    • 8 weeks ≈ 3 vials (26.6 mg total)
    • 12 weeks ≈ 5 vials (40.6 mg total)
    • 16 weeks ≈ 6 vials (54.6 mg total)
  • Insulin Syringes (U‑100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
    • 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Thymosin Alpha-1 10mg Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support immune modulation and enhance host defense mechanisms[1][2].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 300–500 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 7 days.

Dosing Protocol

Suggested daily titration approach.

  • Start: 300 mcg daily for Week 1 to assess tolerance.
  • Target: 500 mcg daily from Week 2 onward.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term; minimize moisture exposure[5].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days when using bacteriostatic water; avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Inspect solution before each use—do not use if cloudy or discolored.

How This Works

Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function through multiple pathways[1]. It enhances the maturation and differentiation of T‑cells, augments dendritic cell function, and promotes the production of key cytokines including interferon‑α and interleukin‑2[2][6]. Clinical studies have demonstrated Tα1’s ability to enhance immune responses in immunocompromised individuals, including those with chronic hepatitis B and C infections[4]. Meta-analyses have also shown benefit in reducing mortality in moderate-to-critical COVID-19 patients[3].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Supports enhanced T‑cell function and overall immune competence[1][2].
  • Demonstrates an excellent safety profile; doses up to 1.6 mg twice weekly for 6–12 months have been well-tolerated[4][7].
  • Even at experimental doses up to 16 mg SC over 12 months, no significant Tα1‑specific toxicity has been observed[7].
  • Most common adverse effect is mild injection‑site irritation (redness or discomfort).

Lifestyle Factors

Complementary strategies for best outcomes.

  • Maintain adequate sleep and stress management to support immune function.
  • Consume a nutrient‑dense diet rich in vitamins C, D, and zinc.
  • Engage in moderate physical activity to complement immune optimization.
  • Avoid excessive alcohol and smoking, which impair immune responses.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[8].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[9][10].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[11].

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • World Journal of Virology
    — Dominari et al. (2020): Comprehensive review of Thymosin Alpha-1 mechanisms, dosing (0.8–6.4 mg SC), and clinical applications
    View Source

  • Molecules (MDPI)
    — Tao et al. (2023): Thymosin Alpha-1 in viral diseases—mechanisms and therapeutic applications in HBV, HCV, and HIV
    View Source

  • Inflammopharmacology
    — Soeroto et al. (2023): Meta-analysis of Tα1 in COVID-19; significant mortality reduction in moderate-to-critical patients
    View Source

  • Expert Opinion on Biological Therapy
    — Thymalfasin (Zadaxin) clinical overview: 1.6 mg SC twice weekly for hepatitis B treatment
    View Source

  • Annals of the New York Academy of Sciences
    — Thymosin Alpha-1: biological activities, clinical applications, and pharmacokinetics review
    View Source

  • Clinical Immunology
    — Mechanisms of thymosin alpha-1 immunomodulation: T-cell maturation and cytokine production
    View Source

  • FDA Peptide Advisory Committee (2024)
    — Safety data: Tα1 doses up to 16 mg SC for 12 months showed no significant toxicity
    View Source

  • Hospital Pharmacy
    — Jordan et al. (2021): Small-volume injection accuracy; recommends ≥20% syringe capacity for precision
    View Source

  • CDC
    — Vaccine administration: subcutaneous route (angle/site; no aspiration required)
    View Source

  • Johns Hopkins Arthritis Center
    — How to give a subcutaneous injection: site selection, rotation, and technique
    View Source

  • NCBI Bookshelf
    — Best practices for injection: asepsis, preparation, site rotation, and administration
    View Source

  • Subcutaneous Drug Injection Review (PMC)
    — Pharmacologic considerations of the subcutaneous route
    View Source

  • Pure Lab Peptides
    — Thymosin Alpha-1 (10 mg) product page (quality and batch documentation)
    View Source